A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-04-04 DOI:10.1080/14760584.2025.2480282

Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Claudia Lindemann, Federico Mensa

引用次数: 0

查看原文本刊更多论文

BNT162b2 COVID-19疫苗现有安全性数据的简明语言摘要：开发、批准和使用监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.